Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses remaining questions in the Phase II METEORA-II trial (NCT02954055) of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel in patients with ER+/HER2- metastatic breast cancer. Quality of life was not assessed in the study, where the preference for oral or intravenous administration is not known. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.